Sorafenib in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than f...
Publications
4 shownNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with prev...
Frequent Co-Authors
Researcher Info
- h-index
- 4
- Publications
- 4
- Citations
- 20,243
- Institution
- University Hospital Foundation
External Links
Identifiers
- ORCID
- 0000-0003-2412-1563
Impact Metrics
h-index
4
h-index: Number of publications with at least h citations each.